MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
prefunded warrants in...
$37,256K
Proceeds from exercise of
stock options
$1K
Net cash provided by
financing activities
$35,707K
Canceled cashflow
$1,550K
Increase in cash, cash
equivalents and restricted...
$12,808K
Canceled cashflow
$22,899K
Payments of issuance
costs included in...
$1,550K
Collaboration and license
agreement receivable
-$5,000K
Stock-based compensation
expense
$2,211K
Depreciation and
amortization
$344K
Net cash (used in)
provided by operating...
-$22,343K
Net cash used in
investing activities
-$556K
Canceled cashflow
$7,555K
Deferred revenue
-$12,648K
Net loss
-$9,529K
Change in fair value of
common stock warrant...
-$3,300K
Purchases of property and
equipment
$556K
Accounts payable
-$1,680K
Accrued expenses and
other liabilities
-$1,536K
Prepaid and other assets
$1,205K
Back
Back
Cash Flow
source: myfinsight.com
Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc. (XLO)